Notable Labs debuts by acquiring volasertib rights

Coming out of stealth, US developer of predictive precision medicines Notable Labs is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes Biosciences, which gained rights to the investigational compound from Germany’s Boehringer Ingelheim in 2019.

Notable will leverage its high-fidelity predictive precision medicines platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development in this patient population.

Notable’s proprietary platform was built upon deep expertise across therapeutics, diagnostics, software, engineering, machine learning and automation. It quickly determines the response profile of individual patients prior to their cancer treatment, allowing for selective enrollment of predicted clinical responders into clinical trials.